PuSH - Publication Server of Helmholtz Zentrum München: Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Sethunath, V.* ; Hu, H.* ; de Angelis, C.* ; Veeraraghavan, J.* ; Qin, L.* ; Wang, N.* ; Simon, L. ; Wang, T.* ; Fu, X.* ; Nardone, A.* ; Pereira, R.* ; Nanda, S.* ; Griffith, O.L.* ; Tsimelzon, A.* ; Shaw, C.* ; Chamness, G.C.* ; Reis-Filho, J.S.* ; Weigelt, B.* ; Heiser, L.M.* ; Hilsenbeck, S.G.* ; Huang, S.* ; Rimawi, M.F.* ; Gray, J.W.* ; Osborne, C.K.* ; Schiff, R.*

Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer.

Mol. Cancer Res. 17, 2318-2330 (2019)

Publ. Version/Full Text

DOI

PMC

	Free by publisher

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

Despite effective strategies, resistance in HER2(+) breast cancer remains a challenge. While the mevalonate pathway (MVA) is suggested to promote cell growth and survival, including in HER2(+) models, its potential role in resistance to HER2-targeted therapy is unknown. Parental HER2(+) breast cancer cells and their lapatinib-resistant and lapatinib + trastuzumab-resistant derivatives were used for this study. MVA activity was found to be increased in lapatinib-resistant and lapatinib + trastuzumab-resistant cells. Specific blockade of this pathway with lipophilic but not hydrophilic statins and with the N-bisphosphonate zoledronic acid led to apoptosis and substantial growth inhibition of R cells. Inhibition was rescued by mevalonate or the intermediate metabolites farnesyl pyrophosphate or geranylgeranyl pyrophosphate, but not cholesterol. Activated Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) and mTORC1 signaling, and their downstream target gene product Survivin, were inhibited by MVA blockade, especially in the lapatinib-resistant/lapatinib + trastuzumab-resistant models. Overexpression of constitutively active YAP rescued Survivin and phosphorylated-S6 levels, despite blockade of the MVA. These results suggest that the MVA provides alternative signaling leading to cell survival and resistance by activating YAP/TAZ-mTORC1-Survivin signaling when HER2 is blocked, suggesting novel therapeutic targets. MVA inhibitors including lipophilic statins and N-bisphosphonates may circumvent resistance to anti-HER2 therapy warranting further clinical investigation.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Yap; Growth; Activation; Lapatinib; Promotes; Chemotherapy; Simvastatin; Reductase; Apoptosis; Transcription

ISSN (print) / ISBN 1541-7786

e-ISSN 1557-3125

Journal Molecular Cancer Research

Quellenangaben Volume: 17, Issue: 11, Pages: 2318-2330

Publisher American Association for Cancer Research (AACR)

Publishing Place 615 Chestnut St, 17th Floor, Philadelphia, Pa 19106-4404 Usa

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Computational Biology (ICB)